Icon
+91 94997 68112
Login Register

SCEMBLIX - (100MG)

ASCIMINIB HYDROCHLORIDE None
100MG
Less Than $1000 mn
None None
None None
None None
SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). • Ph+ CML in CP with the T315I mutation.
Yes
SCEMBLIX Patent 1 Patent 2 Patent 3 Patent 4
*** *********

SCEMBLIX - (20MG, 40MG)

ASCIMINIB HYDROCHLORIDE None
20MG, 40MG
Less Than $1000 mn
None None
None None
None None
SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). • Ph+ CML in CP with the T315I mutation.
Yes
SCEMBLIX Patent 1 Patent 2 Patent 3 Patent 4
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.